Generation and characterization of a recombinant
Newcastle disease virus expressing the red
fluorescent protein for use in co-infection studies

Jinnan Li1,2, Haixia Hu1,3, Qingzhong Yu1, Diego G Diel1, De-shan Li4 and Patti J Miller1*

Abstract

Background: Many viruses have evolved multiple strategies to prevent super infection of host cells by more than one virion. This phenomenon, known as super infection exclusion, may play an important role on virus evolution because it can affect the frequency of reassortment and/or recombination. Newcastle disease virus (NDV), a negative sense single-stranded RNA virus, is characterized by its continuous evolutionary dynamics and by a low frequency of recombination events. However, the mechanisms that contribute to the low recombination rates on NDV are still not completely understood.

Methods: In this study we assessed the ability of two NDV strains (LaSota and B1) to super infect host cells in vitro. We generated a recombinant NDV strain LaSota expressing the red fluorescent protein (RFP) and used it in co-infection assays with a related NDV strain B1 expressing the green fluorescent protein (GFP). DF-1 cells were inoculated with both viruses at the same time or at different intervals between primary infection and super infection.

Results: When both viruses were inoculated at the same time point, a 27% co-infection rate was observed, whereas when they were inoculated at different time points the super infection rates decreased to levels as low as 1.4%.

Conclusions: These results indicate that although different NDV strains can co-infect host cells in vitro, the super infection rates are low, specially as the time between the primary infection and super infection increases. These results confirm the occurrence of super infection exclusion between different strains of NDV.

Keywords: NDV, Co-infection, Super infection, Interference

Introduction

Newcastle disease (ND) is one of the most important diseases of poultry, causing significant economic losses to poultry producers around the world [1]. The etiologic agents of ND is Newcastle disease virus (NDV), or avian paramyxovirus type 1 (APMV-1), an enveloped, non-segmented, single-stranded, negative sense RNA ([–]ssRNA) virus of the genus Avulavirus family Paramyxoviridae [1]. The NDV genome is approximately 15.2 Kb in length and contains six genes encoding for the nucleoprotein (NP), the phosphoprotein (P), the matrix protein (M), the fusion protein (F), the hemagglutinin-neuraminidase (HN), and the RNA-dependent RNA polymerase (L). At least one additional protein (V) is produced through editing of the phosphoprotein messenger RNA (mRNA) [1,2].

NDV is known for its continuous evolutionary dynamics, with different isolates undergoing simultaneous evolutionary changes around the world [2,3]. This evolutionary dynamic is likely resultant from the lack of proofreading activity of the viral RNA dependent RNA polymerase [4,5]. While mutations introduced during virus replication seem to play a major role on NDV evolution, recombination has only been rarely reported [3,6-9]. In general, the low frequency of recombination in [–]ssRNA viruses reflect specific aspects of their life cycle, including their genome
organization and the mechanisms involved in transcription and replication [10]. Other aspects the infection cycle and virus-host interactions may also affect the recombination rates in RNA viruses [10]. For NDV, however, the strategies/mechanisms that contribute to the low frequency of recombination are not completely understood.

Many enveloped viruses have evolved mechanisms to prevent infection of host cells by more than one virion [11-13]. This phenomenon, known as super infection exclusion, likely affects the frequency of recombination within a viral population because co-infection of a cell by related viruses is required for the exchange of genetic material. In this study we assessed the ability of two NDV strains (LaSota and B1) to super infect host cells in vitro. We generated a recombinant NDV strain LaSota, encoding the red fluorescent protein (RFP; rLS-RFP) and used it in co-infection assays with a related strain of NDV (B1) expressing the green fluorescent protein (GFP; rB1-GFP).

**Methods**

**Cells and viruses**

HEP-2 (ATCC, CCL-23), Vero (ATCC, CCL-81) and DF-1 (ATCC, CRL-12203) cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and antibiotics and antifungal (100U/ml Penicillin, 100 µg/ml Streptomycin, 0.25 µg/ml Amphotericin B, Thermo Scientific), and maintained at 37°C with 5% CO₂. DF-1 cells were supplemented with 10% allantoic fluid (AF) (from specific pathogen free [SPF] embryo-embryonated chicken eggs) during all virus infections. The NDV strain LaSota was obtained from ATCC and the recombinant NDV strain B1 expressing the green fluorescence protein (rB1-GFP) was kindly provided by Dr. Peter Palese, Department of Microbiology, Mount Sinai University [14]. All viruses were propagated in 9-day-old SPF embryo-embryonated chicken eggs and the virus titres were determined by limiting dilution, calculated according to the Spearman and Karber’s method, and expressed as Log₁₀ tissue culture infectious dose 50 (TCID₅₀)/ml. The modified vaccinia virus Ankara/T7 (MVA/T7) was used in the infection/transfection experiments to rescue the recombinant virus NDV-LS/RFP.

**Generation of the recombinant NDV-LaSota containing the RFP gene**

The recombinant NDV LaSota expressing the red fluorescent protein (RFP) (rLS-RFP) was generated from the backbone of the vector pLS/aMVP-C G [15]. The open reading frame of the RFP was inserted between the fusion (F) and hemagglutinin-neuraminidase (HN) genes as an extra transcriptional unit (Figure 1). Initially, an intermediate plasmid containing the aMPV-C G gene and its flanking regions (including the NDV gene start [GS] and gene end [GE] sequences) was generated by PCR amplification (primers: LSFF-5’-TCAGATGAGGCCACTACAAAAAAGTGAGC-3’ and LS6682R-5’-ACTCAAGGGCCACTTGTGATT-3’) and cloning of the PCR product into the TOPO TA® vector (Invitrogen). The aMPV-C G protein coding sequence was replaced with the open reading frame (ORF) of the RFP gene using the In-Fusion® PCR Cloning kit (Clontech) and two sets of primers (including LS-NI-up-5’-CTTGCACCTGGAGGGCGCCAAC-3’ and LS-NI-down-5’-CGTACACAGATGAGGAAACAGGTGGTG-3’) to linearize the vector, and NI-RFP-F-5’-CTTCCCTAGGTGCAAGATGGCCCTCCATCGGCTACAGGACCAGGTCG-3’ and NI-RFP-R-5’-CTTCATCTGTGTACGCTACAGGCTACAGGACCAGGTCG-3’.

![Mock, rLaSota, rB1-GFP, rLS-RFP](image)

*Figure 1* Cytopathic effect and expression or RFP and GFP in rLS-RFP- and rB1-GFP-infected DF-1 cells. Cells were inoculated with each virus at a MOI of 0.01 and examined under a fluorescence microscope 24 and 48 h pi.
to amplify the RFP ORF from the pCMV-DsRed-Express plasmid, Clontech). The coding sequences of the RFP and its flanking regions were PCR amplified (primers: LSFF and LS6682R, described above) and cloned into the vector containing the full-length LaSota genome using the InFusion PCR cloning kit and specific primers (LS-vec-F-up-5′-GTGGCTCTCATCTGATCTAGAGTATTATTC-3′ and LS-vec-6682-down-5′-AAATGGGCCCCCTTGAATCTCGGT TGCCATTGTAAA-3′). The resultant plasmid, designated pLS-RFP, was amplified in Stbl2 competent cells (Invitrogen) and purified using a QIAprep Spin Miniprep kit (Qiagen).

Rescue of the rLS-RFP was performed in HEp-2 cells according to standard protocols [15]. HEp-2 cells were seeded on a six-well plate (1×10⁶ cells/well), infected according to standard protocols [15]. HEp-2 cells were and purified using a QIAprep Spin Miniprep kit (Qiagen). pLS-RFP, was amplified in Stbl2 competent cells (Invitrogen) and subjected to three freeze and thaw cycles. Viral titres of rLS-RFP was confirmed by hemagglutination (HA) and fluorescence assays.

Biological characterization of rLS-RFP

The pathogenicity of the rLS-RFP virus was assessed by standard mean death time (MDT) and intracerebral pathogenicity index (ICPI) tests [16]. To compare the cytopathic effect (CPE) induced by rLS-RFP, the parental NDV-LaSota and the rB1-GFP, DF-1 cells were infected with each virus (MOI=0.01) and evaluated under a light microscope at 24 and 48 hours post infection (pi). Growth characteristics of rLS-RFP, NDV-LaSota and the rB1-GFP, DF-1 cells were infected with rLS-RFP or rB1-GFP (MOI=3) and super infected at 1 and 3h pi with rB1-GFP or rLS-RFP (MOI=3), respectively. In a second experiment, cells were inoculated with rLS-RFP or rB1-GFP (MOI=1) and super infected at 12, and 24h pi with rB1-GFP or rLS-RFP (MOI=3), respectively. At 24h post super infection cells were stained with HCS Nuclear Mask Blue (Invitrogen), and examined under a fluorescence microscope (Nikon, Eclipse Ti, Melville, NY). The numbers of red-, green-, and yellow-fluorescent cells were determined as described above. In addition, Vero cells were inoculated with rLS-RFP or rB1-GFP (MOI=3) and super infected at 3h pi with rB1-GFP or rLS-RFP (MOI=3), respectively. At 24h post super infection cells were examined under a fluorescence microscope (Nikon, Eclipse Ti, Melville, NY). Statistical analysis was performed with the two-tailed paired Student’s t-test, and p values < 0.05 were considered statistically significant.

Results

Construction and characterization of recombinant NDV LaSota expressing the red fluorescent protein (rLS-RFP)

The recombinant NDV LaSota encoding the red fluorescent protein (RFP) was constructed using reverse genetic approaches. The cDNA clone pLS/aMPV-C G [15], containing the complete genome sequences of NDV strain LaSota and the coding sequences of the GP of avian metapneumovirus type C, was used as backbone to generate the rLS-RFP virus. The open reading frame of the aMPV G protein (1,758 nt) was replaced by the coding sequence of the RFP (678 nt) using the In-Fusion cloning strategy. The rLS-RFP was rescued in HEp-2 cells and propagated in 9-days-old embryonated chicken eggs. DNA sequencing of regions flanking the inserted gene confirmed the integrity of NDV LaSota and of RFP sequences in the recombinant virus (data not shown).

To determine whether the resultant recombinant virus expresses the RFP, DF-1 cells were infected and examined
under a fluorescence microscope. Expression of RFP was observed in cells infected with the rLS-RFP at 24h and 48h post-infection (pi), demonstrating efficient expression of RFP by the recombinant virus (Figure 1). The rB1-GFP virus was used as a positive control for the expression of GFP (Figure 1).

Biological characterization of the rLS-RFP virus
The pathogenicity and replication kinetics of rLS-RFP were assessed in vivo and in vitro, respectively. The intracerebral pathogenicity index (ICPI) and the mean death time (MDT) of rLS-RFP were determined using standard protocols. Insertion of RFP into the NDV-LaSota backbone resulted in a slight attenuation of the recombinant virus, as evidenced by a decreased intracerebral pathogenicity index (ICPI; 0.0) in day-old chicks and a longer mean death time (MDT; 127 h) in embryonated chicken eggs inoculated with rLS-RFP, when compared to those inoculated with the parental virus NDV strain LaSota (Table 1). The rB1-GFP presented a MDT >150 h. No differences in the cytopathic effect (CPE) induced by the parental and recombinant viruses (rLS-RFP and rB1-GFP) were observed in DF-1-infected cells (Figure 1). Additionally, no significant differences in the replication kinetics and viral yields were detected between NDV-LaSota, rLS-RFP, and rB1-GFP in embryonated chicken eggs- or in DF-1-infected cells (Table 1; Figure 2), indicating that insertion of RFP in the F-HN intergenic region did not significantly affect replication of the recombinant virus.

Super infection with rLS-RFP and rB1-GFP results in low rates of co-infection in vitro
The ability of two NDV strains (LaSota and B1) to super infect host cell was assessed in vitro. DF-1 cells were co-infected with rLS-RFP (MOI=3) and rB1-GFP (MOI = 3) and the expression of RFP and GFP was examined by fluorescence microscopy. Red- and green-fluorescent cells were observed as early as 12 h pi, confirming that the cells were infected with rLS-RFP or rB1-GFP, respectively (Figure 3A). The co-infection rates were ~27% as evidenced by the presence of yellow-fluorescent cells at 24 h pi (Figure 3A, panel a, and d).

The effect of the time of infection on the ability of NDV LaSota and B1 to super infect host cells was also investigated. DF-1 cells were infected with rLS-RFP or rB1-GFP and super infected with rB1-GFP or rLS-RFP at different intervals post-primary infection, respectively (1, 3, 12 and 24 h pi). As in the co-infection assay described above, super infection at intervals of 1, 3, 12 and 24 h resulted in low rates of co-infection, confirming the occurrence of viral interference or super infection exclusion among these viral strains [17] (Figure 4A, B, and C; Figure 5A,B and C). Notably, the co-infection rates significantly decreased as the time between primary infection and super infection increased (Figure 4A,B and C; Figure 5A,B and C). To rule out the possibility that the super infection exclusion observed in DF-1 cells was mediated by a host antiviral response induced by the primary infection, we performed the super infection assays in Vero cells which are defective in interferon production [18]. Similar to the results observed in DF-1 cells, infection with one NDV strain (rLS-RFP or rB1-GFP) interfered with the super infection by the other, as evidenced by low rates of yellow-fluorescent cells at 24 h pi (Additional file 1: Figure S1). These results demonstrate the occurrence of super infection exclusion between two different strains of NDV in DF-1 and Vero cells.

Discussion
In the present study we assessed the ability of two NDV strains (LaSota and B1) to co-infect host cells in vitro. Results here revealed that NDV strains LaSota and B1 are able to co-infect one host cell simultaneously. However, the super infection rates are low and they decrease as the time between the primary infection and super infection increases. These findings suggest the occurrence of super infection exclusion during NDV infection.

Super infection exclusion is a phenomenon by which an established virus infection blocks co-infection by a

Table 1 Biological characterization of the rLS-RFP

| Virus      | MDT  | EID<sub>50</sub> | TCID<sub>50</sub> | ICPI |
|------------|------|-----------------|-----------------|------|
| NDV LaSota | 110hs| 3.20×10<sup>8</sup> | 2.37×10<sup>8</sup> | 0.15 |
| rLS-RFP   | 127hs| 3.60×10<sup>8</sup> | 1.78×10<sup>8</sup> | 0    |
| rB1-GFP   | >150hs| 1.26×10<sup>8</sup> | 1.78×10<sup>7</sup> | NT<sup>a</sup> |

<sup>a</sup>Not tested.
homologous super infecting virus [11]. Here we have shown that primary infection of DF-1 cells with either rLS-RFP or rB1-GFP decreases the co-infection rates by the heterologous strain. Interestingly, the co-infection rates decreased as the time between the primary infection and the super infection increased, corroborating with findings from early studies [17]. Super infection exclusion can occur at three different steps of the virus life cycle, including attachment, entry and/or intracellular replication [11-13]. It has been shown that for the paramyxovirus human parainfluenza type 3 the neuraminidase activity of the HN protein is responsible for blocking super infection by a heterologous strain [13]. Whether NDV HN exerts a similar function in blocking super infection or whether the virus has evolved additional mechanisms to prevent super infection remains to be determined.

Although the biological significance of super infection exclusion for NDV and other paramyxoviruses is unknown, this phenomenon can contribute to the low frequency of recombination observed for these viruses. The limited number of cells that are co-infected during NDV infection may negatively affect recombination rates. As shown here, super infection rates were low even when a high multiplicity of infection (MOI=3 for each virus) was used (Figure 3A and B), and they significantly decreased as the time interval between each infecting virus increased (Figure 4A, B, and C; Figure 5A, B and C). Results from the super infection assays on Vero cells (Additional file 1: Figure S1A and B), known to be interferon defective [18], indicate that the low co-infection rates observed in DF1 cells are due to super infection exclusion between NDV strains LaSota and B1 and not due to an antiviral response of the host cells generated against the primary infection. It is important to note that in addition to specific viral mechanisms that may contribute to super infection exclusion (i.e. neuraminidase activity of the HN protein), the

Figure 3 Co-infection of DF-1 with rLS-RFP and rB1-GFP. (A) Monolayers of DF-1 cells were infected with rLS-RFP and rB1-GFP (MOI=3) at the same time point. At 24h post infection, cells were stained with HCS NuclearMask Blue and examined under a fluorescence microscope. a. merged green, red and blue channels; b. red channel; c. green channel. d. merged green and red channels; e. bright field. (B) Percentage of infected cells. Cells were infected as described in A. Three fields were randomly selected and used to determine the numbers of red-, green- and yellow-fluorescent cells using the ImageJ software. Results shown represent mean percentages of three fields. The percentages of cells infected with each virus (rLS-RFP of rB1-GFP) and the percentage of cells co-infected are expressed as a relative percentage of the total number of infected cells.
Figure 4 Co-infection of DF-1 cells with rLS-RFP and rB1-GFP. (A) DF-1 cells infected with rLS-RFP (MOI=3) and super infected with rB1-GFP (MOI=3) at 1 h post primary infection. At 24h post infection, cells were stained with HCS NuclearMask Blue and examined under a fluorescence microscope. a, merged green, red and blue channels; b, red channel; c, green channel; d, merged green and red channels; e, bright field. (B) DF-1 cells infected with rLS-RFP and super infected with rLS-RFP at 12 h post primary infection. a, merged green, red and blue channels; b, red channel; c, green channel; d, merged green and red channels; e, bright field. (C) Percentage of infected cells. Cells were infected as described in A and B. Three fields for each indicated time point were randomly selected and used to determine the numbers of red-, green- and yellow-fluorescent cells using the ImageJ software. Results shown represent mean percentages of three fields. The percentages of cells infected with each virus (rLS-RFP of rB1-GFP) and the percentage of cells co-infected are expressed as a relative percentage of the total number of infected cells.
Figure 5 Co-infection of DF-1 cells with rB1-GFP and rLS-RFP. (A) DF-1 cells infected with rB1-GFP (MOI=3) and super infected with rLS-RFP (MOI=3) at 1 h pi. At 24h post infection, cells were stained with HCS NuclearMask Blue and examined under a fluorescence microscope. 

a. merged green, red and blue channels;  
b. red channel;  
c. green channel;  
d. merged green and red channels;  
e. bright field.  

(B) DF-1 cells infected with rB1-GFP and super infected with rLS-RFP at 12 h pi. At 24h post infection, cells were stained with HCS NuclearMask Blue and examined under a fluorescence microscope.  

a. merged green, red and blue channels;  
b. red channel;  
c. green channel;  
d. merged green and red channels;  
e. bright field.  

(C) Percentage of infected cells. Cells were infected as described in A and B. Three fields for each indicated time point were randomly selected and used to determine the numbers of green-, red- and yellow-fluorescent cells using the ImageJ software. Results shown represent mean percentages of three fields. The percentages of cells infected with each virus (rB1-GFP or rLS-RFP) and the percentage of cells co-infected are expressed as a relative percentage of the total number of infected cells.
co-infection rates are likely affected by other factors in vivo, including strain-specific cell and tissue tropism, the time interval between infection with different strains and the presence of predisposing immunity.

In the future, it will be interesting to use the recombinant virus generated here (rLS-RFP) to determine the mechanism responsible for super infection exclusion in NDV and to assess the potential for recombination among different NDV strains. Complete genome sequencing following super infection experiments will allow us to determine if recombination can indeed occur in NDV and how frequent it may be.

Conclusions
In summary, the present study describes the characterization of a recombinant NDV strain encoding a red fluorescent protein that was used in co-infection studies. We have shown that NDV strains LaSota and B1 are able to co-infect host cells in vitro, however the co-infection rates are low and they decrease as the time between primary infection and super infection increases.

Additional file
Additional file 1: Figure S1. Co-infection of Vero cells with rB1-GFP and rLS-RFP. (A) Vero cells were infected with rB1-GFP (MOI=3) and super infected with rB1-GFP (MOI=3) at 3 h post primary infection. At 24 h post infection, cells were examined under a fluorescence microscope: a. red channel; b. green channel; c. merged green and red channels. (B) Vero cells were infected with rB1-GFP and super infected with rLS-RFP at 12 h post primary infection. At 24 h post infection, cells were examined under a fluorescence microscope: a. green channel; b. red channel; c. merged green and red channels.

Abbreviations
ND: Newcastle disease; NDV: Newcastle disease virus; APAMV-1: Avian paramyxovirus type 1; [-] ssRNA: Non-segmented single-stranded, negative sense RNA; NP: Nucleoprotein; Pi: Phosphoprotein; M: Matrix protein; F: Fusion protein; HN: Hemagglutinin-neuraminidase; L: RNA-dependent RNA polymerase; mRNA: Messenger RNA; RFP: Red fluorescent protein; ICPI: Intracerebral pathogenicity index; MDT: Mean death time; CPE: Cytotoxic effect; TCID50: Tissue culture infectious dose 50; DMEM: Dulbecco’s modified eagle medium; FBS: Fetal bovine serum; AF: Allantoic fluid; SPF: Specific pathogen free; MVA/T7: Modified vaccinia Ankara/T7; GS: Gene start; GE: Gene end; ORF: Open reading frame; HA: Hemagglutination; MOI: Multiplicity of infection.

Competing interests
The authors declare no competing interest.

Authors’ contributions
JL constructed the recombinant virus and performed the co-infection studies. HH contributed for recombinant virus construction. QY contributed and coordinated the recombinant virus construction. DGD conceived the co-infection studies. DL participated on experimental design. PJM coordinated the research. All authors have read and approved the final manuscript.

Acknowledgments
We thank Tim Olivier and Xiaoxia Qin for technical assistance, the SEPRL sequencing facility personnel for nucleotide sequencing, and Dr. Peter Palese (Department of Microbiology, Mount Sinai School of Medicine) for providing the recombinant virus rB1-GFP used in this study. J. Li and H. Hu were sponsored by a scholarship from China Scholarship Council. This work was supported by USDA funding, CRIS no. 6612-23000-064-00D.

Author details
1 USDA-ARS, Southeast Poultry Research Laboratory, 934 College Station Road, Athens, GA 30605, USA. 2 Heliogiang Fisheries Research Institute, Harbin 150070, China. 3 College of Animal Science and Technology, Southwest University, 2 Tiansheng Road, Chongqing, BeiBei District 400715, China. 4 College of Life Sciences, Northeast Agriculture University, Harbin 150030, China.

Received: 10 May 2012 Accepted: 26 September 2012 Published: 3 October 2012

References
1. Alexander DJ, Senne DA: Newcastle disease, other avian paramyxoviruses, and pneumovirus infections. In Diseases of Poultry. 12th edition. Edited by Saif YM, Fadly AM, Glisson JR, McDougald LR, Nolan LK, Swayne DE. Ames: Iowa State University Press; 2008:75–116.
2. Miller PZ, Decanini EL, Afonso CL: Newcastle disease: evolution of genotypes and the related diagnostic challenges. Infect Genet Evol 2010, 10:26–35.
3. Del DG, da Silva LH, Liu H, Wang J, Miller PZ, Afonso CL: Genetic diversity of avian paramyxovirus type 1: Proposal for a unified nomenclature and classification system of Newcastle disease virus genotypes. Infect Genet Evol 2012, 12:1770–1779.
4. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S: Rapid evolution of RNA genomes. Science 1982, 215:1577–1585.
5. Chare ER, Gould EA, Holmes EC: Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol 2003, 84:2691–2703.
6. Song Q, Cao Y, Li Q, Gu M, Zhong L, Hu S, Wan H, Liu X: Artificial recombination may influence the evolutionary analysis of Newcastle disease virus. J Virol 2011, 85:10409–10414.
7. Qin Z, Sun L, Ma B, Cui Z, Zhu Y, Kitamura Y, Liu W: F gene recombination between genotype II and VII Newcastle disease virus. Virus Res 2008, 131:299–303.
8. Han GZ, He CQ, Ding NZ, Ma LY: Identification of a natural multi-recombinant of Newcastle disease virus. Virus Res 2008, 137:54–60.
9. Zhang R, Wang X, Su J, Zhao J, Zhang G: Isolation and analysis of two naturally-occurring multi-recombination Newcastle disease viruses in China. Virus Res 2010, 151:45–53.
10. Simon-Loree E, Holmes EC: Why do RNA viruses recombine? Nat Rev Microbiol 2011, 9:617–626.
11. Walters KA, Joyce MA, Addison WR, Fischer KP, Tyrrell DL: Super infection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen. J Virol 2004, 78:7925–7937.
12. Lee YM, Tschirner DM, Yun SJ, Frolov I, Rice CM: Dual mechanisms of pestiviral super infection exclusion at entry and RNA replication. J Virol 2005, 79:3231–3242.
13. Honga MA, Gusella GL, Greengard O, Polonskiauskia N, Porrotto M, Moscona A: Mechanism of interference mediated by human parainfluenza virus type 3 infection. J Virol 2000, 74:11792–11799.
14. Park MS, Shaw ML, Munoz-Jordan J, Cios JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF: Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 2003, 77:1501–1511.
15. Hu H, Roth JP, Estevez CN, Zisk L, Liu B, Yu Q: Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys. Vaccine 2011, 29:8624–8633.
16. Alexander DJ: Newcastle disease and other avian paramyxoviruses. Rev Sci Tech 2000, 19:443–462.
17. Bratt MA, Rubin H: Specific interference among strains of Newcastle disease virus. I. Demonstration and measurement of the interference. Virology 1967, 33:596–608.
18. Emerini JM, Morgan MJ: Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 1979, 43:247–252.

doi:10.1186/1743-422X-9-227
Cite this article as: Li et al.: Generation and characterization of a recombinant Newcastle disease virus expressing the red fluorescent protein for use in co-infection studies. Virology Journal 2012 9:227.